It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2018

Evotec publishes DDup 7 – Kidney diseases 2.0
Nerina Coppini, 28 September 2018

In this 7th DDup issue, we delve into the unique new kidney platforms poised to change the trajectory of kidney disease research and therapeutics development. Evotec has embarked on a novel collaboration model with Kidney Research UK, University of Bristol, University of Cambridge, University of Nottingham and the Mario Negri Institute in...

Evotec and Almirall enter into research collaboration in the field of dermatological diseases
Nerina Coppini, 17 September 2018

Collaboration is focused on first-in-class therapies to treat dermatological diseases Collaboration leverages a novel approach to disrupt cell signalling, validated by EVT Innovate

Evotec AG listed in MDAX
Nerina Coppini, 6 September 2018

Dual-listing of Evotec AG share in TecDAX and MDAX as of 24 September 2018 

Evotec and Celgene enter partnership in the field of targeted protein degradation
Nerina Coppini, 6 September 2018

The collaboration will focus on targeted protein degradation Evotec's panomics and data analytics platforms will be leveraged Financials include upfront payment as well as significant potential milestone-based payments and royalties

Yumanity Therapeutics announces first clinical candidate for the potential treatment of Parkinson’s disease
Nerina Coppini, 5 September 2018

First-in-Human Trials Planned for the Fourth Quarter of 2019 IND-Enabling Studies to Be Completed Utilizing Evotec INDiGO Platform

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard